Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00155714

Enrollment

Registered

2005-09-12

Start date

2002-11-30

Completion date

2005-05-31

Last updated

2010-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary and Secondary Pulmonary Hypertension

Keywords

pulmonary arterial hypertension, type-5 phosphodiesterase Inhibitors, Sildenafil

Brief summary

The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

Detailed description

Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil. Efficacy of inhaled NO and Iloprost will also be compared.

Interventions

DRUGtype-5 phosphodiesterase Inhibitor (Sildenafil)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with primary and secondary pulmonary arterial hypertension \-

Exclusion criteria

Unstable patients or patients with allergy to sildenafil

Design outcomes

Primary

Measure	Time frame
mean pulmonary artery pressure	—
6 min walking distance	—
WHO functional status	—
PaO2	—

Secondary

Measure	Time frame
cardiac output	—
VO2max	—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026